Studies of Neuregulin/ERBB Signaling in Human Heart

Launched by DOUGLAS B. SAWYER · Jun 29, 2016

Keywords

ClinConnect Summary

This clinical trial is looking at how certain proteins in the heart, specifically from the epidermal growth factor family, affect heart cells that are not muscle cells. Researchers want to understand their role in heart disease, vascular disease, and heart failure. The study is currently recruiting participants aged 65 to 74 who have been diagnosed with severe coronary artery disease and are scheduled to undergo heart surgery called coronary artery bypass surgery.

If you or a family member are interested in participating, it’s important to know that you must be at least 18 years old and able to provide consent. However, there are certain conditions that would exclude someone from participating, such as active heart inflammation, severe heart or lung issues, or being pregnant. Participants can expect to contribute to valuable research that may help improve treatments for heart-related conditions while being closely monitored for their health throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery.
• Exclusion Criteria:
• • less than 18 years of age
• • unwilling or unable to provide informed consent
• • known active myocarditis
• • hypertrophic cardiomyopathy
• • constrictive pericarditis or other significant pericardial disease
• • severe pulmonary hypertension
• • significant renal impairment (Cr \> 2.5 mg/dL)
• • severe ventricular arrhythmias
• • pregnancy